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Abstract
The prototype polycyclic aromatic hydrocarbon benzo[a]pyrene (B[a]P) is an environmental pollutant and food contaminant
of epidemiological importance. To protect against adverse effects of this ubiquitous carcinogen, we developed an
immunoprophylactic strategy based on a B[a]P-protein conjugate vaccine to induce B[a]P specific antibodies (Grova et al.,
Vaccine. 2009;27:4142–51). Here, we investigated in mice the efficacy of B[a]P-peptide conjugates based on promiscuous T
cell epitopes (TCE) into further improve this approach. We showed that B[a]P-peptide conjugates induced very different
levels of hapten-specific antibodies with variable functional efficacy, depending on the carrier. In some cases peptide
carriers induced a more efficient antibody response against B[a]P than tetanus toxoid as a protein carrier, with the capacity
to sequester more B[a]P in the blood. Reducing the carrier size to a single TCE can dramatically shift the antibody bias from
the carrier to the B[a]P. Conjugates based on the TCE FIGITEL induced the best anti-hapten response and no antibodies
against the carrier peptide. Some peptide conjugates increased the selectivity of the antibodies for the activated metabolite
7,8-diol-B[a]P and B[a]P by one or two orders of magnitude. The antibody efficacy was also demonstrated in their ability to
sequester B[a]P in the blood and modulate its faecal excretion (15–56%). We further showed that pre-existing immunity to
the carrier from which the TCE was derived did not reduce the immunogenicity of the peptide conjugate. In conclusion, we
showed that a vaccination against B[a]P using promiscuous TCEs of tetanus toxin as carriers is feasible even in case of a pre-
existing immunity to the toxoid and that some TCE epitopes dramatically redirect the antibody response to the hapten.
Further studies to demonstrate a long-term protection of an immunoprophylactic immunisation against B[a]P are
warranted.
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Introduction
Benzo[a]pyrene (B[a]P) is a ubiquitous environmental pollutant
and food contaminant belonging to the group of polycyclic
aromatic hydrocarbons (PAH). B[a]P is produced during incom-
plete combustion of organic matter and emanates from natural
and anthropogenic sources including industrial processes, cooking,
barbequing and tobacco consumption [1]. Uptake in humans is
mostly by inhalation of contaminated air, cigarette smoke and
ingestion of contaminated food or water. As a consequence
exposure to B[a]P by the general public is unavoidable.
Known adverse effects of B[a]P include carcinogenicity,
immuno-, neuro-, geno-, reproductive and developmental toxicity
[2–9]. B[a]P is a very effective pulmonary carcinogen in human
and experimentally in rodents [10,11]. The total dose experienced
by a smoker in a lifetime is remarkably close to the lowest total
dose shown to induce tumours in rats [12]. The aryl hydrocarbon
receptor (AhR) plays an important role in B[a]P-induced
carcinogenesis. Human and animal studies showed a significant
correlation between the inducibility of the arylhydrocarbon
hydroxylase activity and lung carcinogenesis induced by B[a]P
[13,14]. B[a]P mediated carcinogenicity can also be induced by its
genotoxicity. Human lung and liver metabolically activate B[a]P
to 7,8-diol-9,10-epoxide-B[a]P (BPDE) by phase one enzymes [15]
(Figure 1). In human lung, DNA adducts of B[a]P have been
detected [16,17]. Metabolic manipulations by isothiocyanates that
decrease the formation of DNA adducts, without lowering levels of
chemical exposure, have been shown to reduce the number of
tumours [16,18]. Mechanistic studies have shown that the
chemopreventive activity of isothiocyanates, that modify carcino-
gen metabolism specifically by inhibiting Phase one enzymes and/
or by inducing Phase two enzymes, result in increased carcinogen
excretion or detoxification and decreased carcinogen DNA
interactions [19]. BPDE adducts have been linked to G:C to
T:A transversions in the Tp53 gene at an unusual series of
mutational hotspot codons in smoking-associated lung cancer [20].
Mutations in critical regions of this tumour suppressor gene or of
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growth and cancer development [21].
Therefore, we have started to develop strategies based on B[a]P-
carrier conjugates to explore the ability of B[a]P specific antibodies
to protect against the adverse effects of this carcinogen [22–27].
The use of hapten-carrier conjugates using proteins for vaccination
have been successful in the case of nicotine and its major
metabolite cotinine, or cocaine using various carrier proteins [28–
31]. Some of these conjugates are already tested in clinical trials
[29,32]. However, only limited data are available for low
molecular weight carcinogens [33–35]. Concerns about local
carcinogenesis at the site of injection are probably unsubstantiated
considering the low doses and the low metabolic activation rates of
(conjugated) B[a]P in muscles in contrast to lung and liver tissues.
Our previous in vitro studies showed that monoclonal
antibodies against B[a]P may provide some protection against
low doses of B[a]P [22,23]. In a bi-compartment model of
polarised Caco-2 cells, we showed that antibodies reduced the
transport of B[a]P and its metabolism by sequestration of B[a]P
and its metabolites in the cell culture supernatant [22]. In addition,
antibodies modulated the kinetic of B[a]P metabolism in HepG2
cells and human peripheral lymphocytes [23].
Our first in vivo experiments demonstrated that a hapten-
protein conjugate vaccine based on tetanus toxoid (TT) and
diphtheria toxoid (DT) in combination with various adjuvants
licensed in humans was able to induce high levels of antibodies in
mice which were specific for B[a]P, its detoxified metabolites and
its activated form, the BPDE [25–27]. Although most experimen-
tal models use high concentrations of B[a]P to achieve an
experimental read out after short-term exposure, such high
concentrations cannot be used to study protection of B[a]P
specific antibodies because they cannot be matched by stoichio-
metric concentrations of specific antibodies. However, environ-
mental relevant concentrations of B[a]P can easily be matched by
the antibody levels obtained by immunisation with B[a]P-TT
conjugates [26] but they do not provide a short-term readout in
relation to their carcinogenicity.
Conjugating the B[a]P to a bulky carrier protein (e.g. TT or
DT) tends to divert the immune response to the immunogenic
carrier protein and away from the hapten [36]. Carrier proteins
have been replaced by small immunogenic peptides to induce
prophylactic or therapeutic T cell responses against pathogens,
tumours and other diseases but not against low molecular weight
compounds such as B[a]P. In this study, we aimed to further
investigate our prophylactic immunisation strategy against B[a]P
using T cell epitope (TCE) peptides to redirect the antibody
response to the hapten. TCEs were selected that were promiscuous
with respect to a large variety of human and mouse MHC class II
molecules.
Materials and Methods
2.1. Peptide synthesis and B[a]P conjugation
Peptides (Table 1) were synthesised by automated solid phase
peptide synthesis using standard Fmoc chemistry on Rink resin on
a Syro II peptide synthesiser (Multisyntech, Witten, Germany).
B[a]P butyric acid (B[a]P-BA, Biochemical Institute of Environ-
mental Carcinogens, Grosshansdorf, Germany, Figure 1B) was
coupled N-terminally to the protected peptide and was washed
3 times each with methanol and ether.
Peptide-B[a]P conjugates were purified by RP-HPLC on the
A ¨KTA explorer 10S system (Amersham Biosciences, Uppsala,
Sweden) on a C18 column (25068 mm, 120A, 5 mm) using a
linear gradient of 25–95% water/acetonitrile (ACN), 0.1% TFA
(v/v) and monitored at 214 nm (max absorption of peptide bond,
[37]) and 297 nm (max absorption of B[a]P-BA) and lyophilized in
an Alpha 24 lyophilisator (Christ, Osterode am Harz, Germany).
B[a]P-BA was coupled to ovalbumin (OVA, Sigma-Aldrich,
Bornem, Belgium) and purified tetanus toxoid (TT, Serum
Institute of India) by adopted two-step zero-length cross-linking
procedure using active esters as described in Grova et al. [25].
2.2. Mass Spectroscopy
Masses of B[a]P-protein and -peptide conjugates were analysed
using a positive ion MALDI-TOF ULTRAFLEX TOF/TOF
mass spectrometry (Bruker Daltonics, Bremen, Germany)
equipped with a 337 nm, 50 Hz N2 laser of 100 mj as described
in [38]. For synthetic peptides the sequence was verified with the
MALDI mass spectrometer using its post-source decay (PSD)
capacity for fragmentation (Sequence Editor of Biotools software,
Bruker Daltonics, Bremen, Germany). The N-terminal linkage of
B[a]P on peptides was determined by MS/MS using an ion trap
mass spectrometer (Agilent 6340 ion trap) equipped with a Chip
Cube interface for infusion at nano flow rate. The parameter
Figure 1. Metabolic activation of B[a]P. (A) During detoxification a small fraction of B[a]P is activated to 7-8-diol-B[a]P which is further converted
to the highly reactive 7,8-dihydroxy-9,10-epoxy-B[a]P (BPDE) the ultimate DNA carcinogen. (B) Chemical structure of the Benzo[a]pyrene butyric acid
isomeric mixture (B[a]P-BA), the derivative used for the conjugation to T cell epitope peptides.
doi:10.1371/journal.pone.0038329.g001
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2000 V; end plate offset 500 V; capillary exit 100 V and tarp drive
85. For CID, the fragmentation amplitude was set to 1.3 V
scanned from 30% to 200% of this value.
2.3. Immunisation with B[a]P-peptide conjugates
All animal experiments were done in compliance with the rules
of the European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the Ministry of
Agriculture, Viticulture and Rural Development (22 December
2008). A group of 6 mice Balb/c (10 week olds, female, Harlan,
Horst, The Netherlands) were immunised as described previously
[26]. Briefly, mice were primed i.p. with 25 mg of B[a]P-peptide or
B[a]P-TT bioconjugates (50 mM ammonium bicarbonate buffer)
on day 0, emulsified in 50% complete Freund’s adjuvant (CFA, v/
v in PBS, Sigma-Aldrich). On days 14, 28 and 42 mice were
boosted i.p. with the same antigen emulsified in 50% incomplete
Freund’s adjuvant (IFA, v/v in PBS, Sigma–Aldrich,). Mock
immunised control group (n=5) was primed with 50% CFA and
boosted with 50% IFA (v/v in PBS) alone.
2.4. Detection of specific antibodies after immunisation
On day 53, mice were bled retro-orbitally and serum antibody
levels were determined in 384-well microtiter plates (Greiner,
Wemmel, Belgium) as described previously [26]. Briefly, microtiter
plates were coated overnight at 4uC with 0.25 mM B[a]P-OVA
(100 mM carbonate buffer, pH 9.6) for detection of B[a]P specific
antibodies or with homologous non conjugated peptides
(VNNESSE–14, –15, FIGITEL–16, –17 or TT) for the quanti-
fication of carrier specific antibodies. After washing, free binding
sites were saturated with 1% BSA at RT for 2 h. After washing,
diluted serum or carcinogen-specific mouse monoclonal antibody
(P9E1R4 produced by immunisation with B[a]P–DT [25]) was
incubated for 90 min at RT. Binding was assessed by alkaline
phosphatase-conjugated goat anti-mouse IgG (1/750 dilution,
ImTec Diagnostics NV, Antwerpen, Belgium) and 4-nitrophenyl
phosphate disodium salt hexahydrate (Sigma-Aldrich). Absor-
bance was measured at 405 nm (Spectromax Plus, Sopachem,
Brussels, Belgium). For relative quantification, endpoint titers
(EPT) were defined as serum dilutions corresponding to 5 fold the
background. Absolute antibody quantification is described in [26]
and Figure 2A and B. For sera with no detectable antibodies,
endpoint titer was set to 200 (highest serum concentration tested).
2.5. Antibody selectivity by competition ELISA
The selectivity of serum antibodies was determined by
competition ELISA as described previously [39]. Briefly, B[a]P-
BA, B[a]P (Sigma–Aldrich) and 7,8-diol-B[a]P (National Cancer
Institute Chemical Carcinogen Reference Standard Repository,
Midwest Research Institute, Kansas City, MO, USA) were used as
competitors to inhibit antibody binding to coated heterologous
B[a]P-conjugate (B[a]P–OVA). For these competition experi-
ments, the optimal amount of coating antigen and the serum
dilution were determined by indirect ELISA as described above.
Table 1. Summery of peptides and their expected and measured masses (mutations in the peptide sequence are in bold).
ID
Origin/Antigen/
[Ref] Position Sequence
Expected
masses
[M+H]
+
Measured
masses
[M+H]
+ D Purity
VNNESSE–3 TT (wt–short) [41] 916–932 B[a]P–PGINGKAIHLVNNESSE 2098.100 2098.278 0.178 70%
VNNESSE–14 TT (wt–long) 909–932 B[a]P–PDAQLVPGINGKAIHL-
VNNESSE
2721.428 2721.513 0.085 95%
VNNESSE–15 TT B[a]P–PDAQLVVGINGKAI-
HLVNNESSE
2723.443 2723.979 0.536 80%
VNNESSE–18 TT B[a]P–AENKPGINGKAIHLVNNESSE 2540.317 2539.942 0.375 40%
VNNESSE–23 TT B[a]P–ALAYYVLPGINGKA-
IHLVNNESSE
2891.537 2891.286 0.251 85%
VNNESSE–24 TT B[a]P–PILFFRLKGINGKAI-
HLVNNESSE
3015.685 3015.178 0.507 80%
PNRDIL–8 TT (wt–short) [43] 1273–1284 B[a]P–GQIGNDPNRDIL 1630.862 1630.836 0.026 95%
PNRDIL–10 TT B[a]P–ALGLVGTHNGQIGNDPNRDIL 2493.328 2493.416 0.088 80%
FIGITEL–6 TT (wt–short) [43] 830–844 B[a]P–QYIKANSKFIGITEL 2044.155 2043.896 0.259 90%
FIGITEL–29 TT (wt–medium) 826–844 B[a]P–NILMQYIKANSKFIGITEL 2515.406 2515.220 0.186 40%
FIGITEL–16 TT (wt–long) 823–844 B[a]P–QSKNILMQYIKANSK1ITEL 2858.592 2858.986 0.394 80%
FIGITEL–17 TT B[a]P–QSKQILMVYIKANSKF-
IGITEL
2843.617 2843.606 0.011 90%
FIGITEL–21 TT B[a]P–AENKQYIKANSKFIGITEL 2486.372 2486.182 0.190 40%
FIGITEL–27 TT B[a]P–ALAYYVLQYIKANS-
KFIGITEL
2837.952 2837.872 0.080 60%
FIGITEL–28 TT B[a]P–PILFFRLKYIKANSKF-
IGITEL
2930.734 2930.340 0.394 80%
SYFPSV–19 TT (wt) [41] 580–599 B[a]P–NSVDDALINSTKIYSYFPSV 2552.299 2552.572 0.273 90%
SYFPSV–20 TT B[a]P–NSVDDALIVSTKIYSYFPSV 2537.324 2537.514 0.190 95%
SYFPSV–22 TT B[a]P–AENKALINSTKIYSYFPSV 2464.319 2464.154 0.165 70%
Tetanus toxoid (TT), wild type (wt).
doi:10.1371/journal.pone.0038329.t001
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coated on 384-well microtiter plates. Sera dilutions were
determined to obtain 70% of saturation. Dilution series of the
competitors were mixed 1:1 with the diluted serum to final
concentrations of 0 to 1024 mM. No competition (highest signal)
and 100% competition (background signal) were determined using
no competitor. The difference between the two values corresponds
to the dynamic range of the assay (D OD max). For each
competitor concentration, the percent binding of antibody was
determined using the following formula:
% binding = [(OD-t e s t– OD+ background)/D OD max *100].
From the resulting inhibition curves, the 50% inhibition
concentration (IC50) of each competitor was determined. In mice
without selectivity, the IC50 were actively set to 1 mM. A low IC50
value corresponds to high selectivity.
2.6. Distribution of [
3H]-B[a]P in immunized mice after a
single injection
The quantification of [
3H]-B[a]P in organs and excretion
products were described before [25]. Briefly, two weeks after a
complete immunisation schedule, each animal received a single
i.p. injection of [
3H]-B[a]P (2 mg/kg, 2.67 10
4 Bq/mouse GE-
Healthcare, Belgium) and were placed in individual metabolic
cages (Technilab, Someren, Netherlands). Urine, faeces and
organs (Liver, Lung, Brain, Spleen, and Kidney) were collected
24 h later and stored at – 20uC before analysis. EDTA-blood
(500 mL) was obtained by retro-orbital bleeding and analysed
immediately. To study the pharmacokinetic of B[a]P, mice were
challenged with 2 mg/kg [
3H]-B[a]P (2.67 10
4 Bq/mouse) and
sacrificed after 15 min to 48 h intervals. Samples were collected
and stored as described above.
Samples were analysed for [
3H]-B[a]P recovery as described
previously [39]. Pre-hydrated faeces (20 mg) or tissues (100 mg)
were solubilised in Soluene-350 according to Perkin Elmer
procedure and previously described and measured for radioactiv-
ity [40]. All samples were corrected for quenching of radioactivity.
Radioactivity was expressed in Bq or Bq/g accounting for the
effective counting efficiency.
Results
3.1. T cell epitope peptide synthesis and B[a]P
conjugation
After solid phase synthesis peptides were purified by liquid
chromatography and analysed by positive ion MALDI-TOF
ULTRAFLEX TOF/TOF mass spectrometry for their correct
masses. All synthesised peptides had the correct molecular mass
(Table 1). The Figure 3B shows as an example the MS spectrum of
peptide VNNESSE-14. After conjugation, the mass spectra
showed the correct shift in size of 320 Da corresponding to
B[a]P-BA (Figure 3B and E). In addition, a shift in the elution
from the HPLC from 61.5% to 86.5% ACN confirmed the
successful conjugation of B[a]P-BA to the peptide by its increased
hydrophobicity (Figure 3A and D).
The peptide sequence and the N-terminal linkage of the B[a]P-
BA were also confirmed by MS/MS analysis. The peak of 320.64
Figure 2. Anti-B[a]P antibody concentration determined by
indirect ELISA and correlation with antibody levels. To estimate
absolute antibody concentrations a standard curve (insert in panel B)
was used, that was based on dilution curves (1/200–1/437,400) of
different known concentrations (0.01–1 mg/ml, represented by a line
for each concentration in panel A) of purified monoclonal antibody
against B[a]P (P9E1R4). 1/16,200 dilution (dashed line) was chosen to
plot the standard curve (Insert in panel B, R
2=0.9709) and to calculate
the antibody concentration. (B) Example of a titration curve of serum
antibodies of mice immunised with B[a]P conjugated TT 2 weeks after
the fourth injection. Values are presented as mean 6 S.E.M of 6 mice
per group. (C, D) Correlation between antibody level and [
3H]-B[a]P
recovery after a single i.p. injection of 2 mg/kg [
3H]-B[a]P in individual
mice mock immunised and immunised against B[a]P using B[a]P-
peptide or B[a]P-TT conjugates. [
3H]-B[a]P recovery in the blood (C) and
liver (D). The statistical significant relationship between the two
variables as shown in C and D was estimated by linear regression.
doi:10.1371/journal.pone.0038329.g002
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+ molecule (Figure 2F). The
mass difference of 320.64 Da (corresponding to the [B[a]P-
BA+H]
+) between the b2 ions in Figure 3F and C proves the N-
terminal linkage.
3.2. Detection of B[a]P- specific antibodies after
immunisation with B[a]P-peptides
Four known TCE of different length of TT were conjugated to
B[a]P-BA (VNNESSE-3, -14, FIGITEL-6, -16, -29, PNRDIL-8
and SYFPSV-19, Table 1) and tested for their potential to induce
B[a]P specific antibodies. These peptides reacted with mouse H2
d
and were promiscuous for human MHC class II molecules [41–
44]. For instance according to the literature FIGITEL peptides
react with most DR and some DQ and DP MHC class II
molecules whereas PNDRL and SYFPSV peptides react with a
variety of human DR molecules and some mouse class II
molecules [42,44]. In addition, B[a]P was conjugated to several
of variants of these TCE peptides. The serum of each mouse was
titrated 2 weeks after the fourth injection. Figure 4 shows the
variable immunogenicity of a selection of B[a]P-peptide conju-
gates. From B[a]P conjugates based on VNNESSE-motive only
VNNESSE-14 and -15 (EPT 1/120,000 and 1/250,000) induced
higher levels of specific antibodies against B[a]P (Figure 4A and E)
than the B[a]P-TT protein conjugate (EPT 1/99,500, Figure 4E)
but EPT did not significantly differ. All other VNNESSE-peptides
induced significantly lower levels or no antibodies (Figure 4A and
E). Peptide conjugates from the FIGITEL group which induced
higher levels of B[a]P specific antibodies than B[a]P-TT included
FIGITEL-16 and -17 (EPT 1/300,000 and 1/325,000 respective-
ly, Figure 4B and E). Only peptide SYFPSV-20 (EPT 1/19,000,
Figure 4C and E) induced specific antibodies in the group of
SYFPSV peptides, but less efficient than B[a]P-TT. None of the
tested peptides of the PNRDIL-motive induced specific B[a]P
antibodies (Figure 4D).
3.3. Detection of carrier specific antibodies after
immunisation with B[a]P-peptides
The sera with the highest titers against B[a]P were further tested
for antibodies against the homologous carrier peptide. Mean
antibody levels were 6.5 times lower for VENNESSE-14 (EPT 1/
60,000) and 3 times lower for VENNESSE-15 (EPT 1/125,000)
compared to immunisation with B[a]P-TT (EPT 1/390,000
Figure 4F). Interestingly for the FIGITEL-16 and -17 conjugates
no antibodies against the carrier were detected (EPT ,1/200).
3.4. Antibody selectivity by competitive ELISA
The selectivity of the anti-B[a]P antibodies was analysed by
competitive ELISA in all sera of mice with detectable antibodies
against B[a]P. In a competitive ELISA assay IC50 values inversely
correlate with the selectivity for the competitor. IC50 values for
B[a]P-BA as competitor ranged from 0.7 mM for B[a]P-peptide
conjugate VNNESSE-18 to 1.20 mM for FIGITEL-16 (Figure 5A).
Compared to B[a]P-TT, the antibodies induced by VNNESSE-
15, -18, FIGITEL-17, -21 and SYFPSV-20 showed a somewhat
higher selectivity for B[a]P-BA (although not statistically signifi-
cant). Competition with B[a]P, gave IC50 values that were 5 to
30 times higher than those of B[a]P-BA (except for VNNESSE-16
with similar IC50 values) ranging from 0.14 mM for B[a]P-peptide
conjugate VNESSE-15 to 17.00 mM for FIGITEL-16 (Figure 5B).
The IC50 of 7,8-diol-B[a]P was also higher than those of B[a]P-BA
ranging from 0.45 mM (VNESSE-15) to 9.25 mM (VNESSE-14,
Figure 5C). All tested peptide conjugates, except the FIGITEL-16,
showed also a higher selectivity for B[a]P and 7,8-diol-B[a]P than
the TT protein conjugate.
3.5. Modulation of [
3H]-B[a]P distribution in immunised
mice 24 h after a single injection
[
3H]-B[a]P recovery in the blood was on average 3-6 times
higher than in mock immunised animals (p,0.05, Figure 6A) for
Figure 3. Peptide conjugation. HPLC chromatogram before purification (A, D). MS/MS spectrum (B, E) and the N terminal sequence (C, D) of
VNNESSE-14 after purification. Panel A, B, C represent the unconjugated and panel D, E and F the B[a]P-BA conjugated peptide.
doi:10.1371/journal.pone.0038329.g003
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14 and -15 increased [
3H]-B[a]P recovery above the level of
B[a]P-TT immunised animals but the difference was not
statistically significant (Figure 6A). In the different solid tissues
tested [
3H]-B[a]P recovery was on average 1.1-2.6 fold increased
(Figure 6B–F). The difference compared to the mock immunised
animals was highest in the liver (Figure 6B) and the spleen
(Figure 6D) for VNNESSE-14 and VNNESSE-15 (but this did not
reach statistical significance) respectively. No difference was
observed in the brain (Figure 6C). Animals immunised with
FIGITEL-16 showed no enhanced retention of [
3H]-B[a]P in any
of the four organs tested. In faeces, a significant decrease of 15–
56% of the radioactivity recovered was observed (p,0.05) in mice
immunised with peptide conjugates (except for FIGITEL–16)
Figure 4. Antibody titration curves of sera from mice immunised with B[a]P-peptide conjugates. (A) VNNESSE-variants, (B) FIGITEL-
variants, (C) SYFPSV-variants and (D) PNRDIL-variants. Control mice were immunised with B[a]P conjugated to TT-protein (dashed line). Values are
mean of 6 mice per group determined by indirect ELISA using heterologous conjugates (B[a]P-ovalbumin) as coated antigen. (E) Serum endpoint
titers (serum dilution reaching 5 times the background) of B[a]P specific IgG antibodies of individual mice (#) and median value (–). Groups
correspond to a selection of panel A to D. Dashed line represents the endpoint titer for immunisation with tetanus toxoid. (F) Endpoint titers against
homologous carrier peptide. For sera with no detectable antibodies endpoint titers were set to 1/200. Results are presented for each mouse (#) and
median value (–). ***p,0.001, statistically significant difference from TT immunised mice (One Way ANOVA test followed by Student-Newman-Keuls
t-test for multiple comparison).
doi:10.1371/journal.pone.0038329.g004
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Excretion of radioactive B[a]P in the urine was essentially the
same in both immunised and mock control mice (Figure 6G). Fig 5
shows that there is a good and highly significant correlation
between increasing B[a]P antibody concentration and levels of
[
3H]-B[a]P recovered in the blood and in the liver (Figure 2C
and D).
3.6. Modulation of the pharmacokinetic of [
3H] -B[a]P
The pharmacokinetic of B[a]P was investigated over 48 h in
blood, solid tissues and excretion products in mice immunised with
peptide VNNESSE-14 (Figure 7). In mock immunised mice a
rapid accumulation of [
3H]-B[a]P was observed in the blood with
peak concentrations 3 h after B[a]P administration (Figure 7A). In
B[a]P immunised mice a significantly higher peak was observed
4.5 h after B[a]P injection and was constant for at least 48 h
(Figure 7A). In solid tissues, the highest levels of B[a]P were
detected in the liver and the kidney, the lowest in the brain 3-4.5 h
after injection. In B[a]P immunised mice, the peak concentration
was delayed by 1-2 h. In kidney and brain, the concentration of
B[a]P was lower in the immunised group during the uptake phase
(first 10 h), and was then constant over the observation period,
while a decrease was observed for the kidney in the control group
(Figure 7C and E). For the other organs tested (liver, spleen, lung)
no difference was observed early after B[a]P administration
(Figure 7B, D and F). As a consequence of B[a]P sequestration by
antibodies, excretion in the urine and faeces was reduced
(Figure 7G and H). In the urine of immunised mice, lower levels
of B[a]P were detected during the first 18 h, whereas in the faeces
this difference was only observed during the first 3 h (Figure 7G
and H).
3.7. Effect of a TT pre-vaccination on the B[a]P
vaccination
The influence of a pre-existing immune response to the carrier
protein (TT) was tested by immunising mice with TT prior to
immunisation with B[a]P-peptides and B[a]P-TT. Antibody levels
in mice pre-immunised with TT were higher or similar to those
without pre-vaccination, excluding a negative effect of pre-existing
antibodies to TT (Figure 8B). Also the antibodies against TT were
not influenced by a vaccination with B[a]P-peptide conjugates
(Figure 8A). There was also no negative effect of TT pre-exposure
on antibody specificity for B[a]P or 7,8-diol-B[a]P (Figure 8C and
D). The in vivo recovery experiment also reflected this observation
(Figure 9). 24 h after [
3H]-B[a]P injection the recovery of
radioactivity was similar for FIGITEL-16 and -17 compared to
those without pre-vaccination and for VNNESSE-14 and -15 it
was even significantly increased.
Discussion
In our previous work we showed that the conjugation of B[a]P-
BA to TT or diphtheria toxoid (DT) induces high titers of B[a]P-
specific antibodies [25]. Here we demonstrate that similar or even
better B[a]P-specific antibody titers can be induced by reducing
the carrier size to a single promiscuous TCE.
It was previously shown that vaccination with a co-linear
peptide containing a peptide corresponding to an important
neutralising epitope of the measles hemaglutinin protein and
various TCEs induced antibodies with activities that ranged from
simply binding to in vitro neutralisation and in vivo protection
against the virus [45]. Similarly, we here show that TCE-peptides
induced very different levels of hapten specific antibodies with
varying functional efficacies, depending on the carrier peptide. In
some cases the peptide carrier induced a more efficient immune
response than the protein conjugates. Not all known TCE-peptides
[41–43] induced hapten specific antibodies (Figure 4A), which
may reflect difficulties of the antigen processing and presentation
machinery to properly cleave the conjugate.
Peptide conjugates are simple and cost effective to synthesise in
large quantities, in high quality and safety [46]. In addition,
peptide carrier conjugates are stoichiometrically well defined
(Figure 3F) which is not the case of protein conjugates. The TT-
protein carrier conjugate had on average 8 haptens per molecule,
corresponding to 1 hapten for 18 kDa of protein [25], while the
hapten/carrier ratio was 1 in the case of the peptide conjugate,
Figure 5. Antibody selectivity determined by competitive
ELISA in sera immunised with B[a]P peptide or TT conjugates.
(A) B[a]P-BA, (B) B[a]P, and (C) 7,8-diol-B[a]P were used as competitors
to compete for binding of specific antibodies to B[a]P-ovalbumin as the
coated antigen. The IC50 (concentration of competitor for 50%
inhibition) was calculated as a measure of antibody selectivity for each
tested competitor. The IC50 is inversely correlated to the antibody
selectivity. Results are represented for each mouse (#) and median
value (–).*p,0.05, statistically significant difference from TT immunised
mice (One Way ANOVA on Ranks followed by Dunn’s method).
doi:10.1371/journal.pone.0038329.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e38329Figure 6. B[a]P recovery in mice immunised against B[a]P. [
3H]-B[a]P (in Bq/g tissue weight or Bq) recovered in blood (A), tissues (B–liver, C–
brain, D–spleen, E–kidney, F–lung), urine (G) and faeces (H) 24 h after a single i.p. injection of [
3H]-B[a]P (2 mg/kg) in B[a]P-peptide, B[a]P-TT or mock
Vaccination against B[a]P with Peptide Conjugates
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e38329immunised mice. Results are expressed as mean 6 S.E.M of 5 mice per group. *p,0.05; statistical significant difference from control (Mock) (Student-
Newman-Keuls-t test for multiple comparisons).
doi:10.1371/journal.pone.0038329.g006
Figure 7. B[a]P pharmacokinetic. Pharmacokinetic of [
3H]-B[a]P in mice immunised with VNESSE-14 (#) and mock immunised mice (#) over
48 hours after a single i.p. injection of 2 mg/kg [
3H]-B[a]P. (A) blood, (B) liver, (C) brain, (D) spleen, (E) kidney, (F) lung, (G) urine, (H) faeces. Results are
expressed as mean 6 S.E.M of 5 mice per group. *p,0.05; **p,0.01 and ***p,0.001, statistical significant difference from controls (Two way ANOVA
procedure followed by Student-Newman-Keuls-t test).
doi:10.1371/journal.pone.0038329.g007
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simplest assumption that the molecular weight is a crude estimate
of the relative number of B cell epitopes (BCEs), the peptide
conjugate would have a six fold better ratio of hapten to carrier
BCEs. Indeed, while some peptide conjugates induced similar or
even higher anti B[a]P titers, antibody levels against the carrier
peptide was up to 6 fold lower for some of the VNESSE
conjugates. Interestingly, the conjugate FIGITEL-16 and -17
induced the best anti-hapten responses and no antibodies against
the carrier peptide. Although this may be suggestive of a hole in
the B cell repertoire despite a strong T cell immunogenicity against
the latter peptide, vaccine conjugate based on appropriate small
peptide carriers strengthen the B cell response towards the hapten
at the detriment of the carrier.
Some peptide conjugates did not only induce similar or higher
levels of antibodies against B[a]P, but they also showed an
increased specificity and an improved ability to sequester [
3H]-
B[a]P. In particular peptide VNESSE-14 and -15 showed an
improved immune response in terms of antibody quantity, quality
and B[a]P sequestration in the blood.
Our TCE were derived from TT, against which 90% of the
world population is vaccinated. Thus a large proportion of a
population will have T cells specific for the promiscuous TCE
selected here. To exclude that a pre-existing T cell immunity
against TT interfere with the immune response against the TCE
(from TT) undermining the anti-hapten antibody response, we
tested the effect of a TT pre-vaccination on the vaccination with
B[a]P peptide-conjugates. B[a]P antibody levels were in general
higher in pre-immunised animals for all peptide conjugates tested
(except for FIGITEL-16, Figure 8). Also antibody specificity and
effectiveness did not suffer as a result of pre-vaccination with TT,
for most of the peptide conjugates. In fact, the recovery of [
3H]-
Figure 8. Immunogenicity of B[a]P-peptide conjugates after tetanus toxoid pre-vaccination. (A) Endpoint titers (serum dilution reaching
5 times the background) for TT specific IgG antibodies determined by indirect ELISA for sera pre-immunised with tetanus toxoid (TT) followed by
B[a]P-peptide or B[a]P-TT conjugate vaccination. (B) B[a]P specific IgG antibodies with and without pre-vaccination. Results are presented for each
mouse (#) and median value (–). There was no statistical significant difference between animal with and without pre-vaccination (One way ANOVA
procedure followed by Student-Newman-Keuls-t test). (C, D) Antibody selectivity determined by competitive ELISA in sera immunised with B[a]P
peptide or B[a]P-TT conjugates with (#) and without (N) tetanus toxoid (TT) pre-vaccination. B[a]P (C) and 7,8-diol-B[a]P (D) were used as
competitors to compete for binding of specific antibodies to B[a]P-ovalbumin as the coated antigen. The IC50 (concentration of competitor for 50%
inhibition) was calculated to determine the antibody specificity for each tested competitor. The IC50 is inverse correlated to the antibody affinity.
Results are presented for each mouse (circle) and median value (–).
doi:10.1371/journal.pone.0038329.g008
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and boosted with VNESSE-14 and -15. These results are in
agreement with Putz et al. who tested the immunogenicity of B
cell epitope peptides conjugated to DT or TT derived TCE in
mice after active priming with the toxoids [47]. Both TT and DT
peptide conjugates induced high titers of anti-measles antibodies
which cross-reacted with the virus and protected against a lethal
challenge with the virus, even after active priming with the
homologous toxoid [47]. Similar observations were found in
humans, active priming against the carrier enhanced the response
to the antigen conjugated to TT and DT irrespective of whether
proteins, or peptides were used [48–51].
Kinetic experiments showed that B[a]P specific antibodies
modulate the pharmacokinetics and slow down its excretion by
capturing B[a]P or its metabolites in the blood stream and by
reducing its excretion via the faeces (Figure 2H). The higher levels
of B[a]P recovered in solid tissues in immunised mice are due to
sequestration by antibodies and not by the blood in the organs.
The results are in accordance with Johanson and colleagues who
showed a higher recovery of dinitrophenol in the liver (20% in
spleen and 50% lung) in rats passively immunised with anti-
dinitrophenol antibodies [52]. B[a]P specific antibodies are able to
capture B[a]P or its metabolites in the blood away from sensitive
tissues and thereby mitigating P450 enzyme induction and
reducing its metabolism especially to its toxic metabolite 7,8-
diol-9,10-epoxide-B[a]P. In general antigen-antibody complexes
are depleted mostly by Kupffer cells of the reticuloendothelial
system of the liver [52–54]. Because of the lower sensitivity of the
liver to B[a]P carcinogenesis, metabolism of B[a]P in this organ is
much less likely to cause damage. In addition, we can speculate
that the sequestration by specific antibodies of environmental (i.e.
very low) concentrations of B[a]P (mean daily uptake 200 ng [55])
would be considerably higher resulting in an even better protective
effect against its toxicity.
In previous experiments we demonstrated in vitro and in vivo
that B[a]P specific antibodies are also able to capture its endpoint
metabolites and the 7,8-diol which is the precursor of the ultimate
carcinogen 7,8-diol-9,10-epoxide-B[a]P [23,26]. In addition, our
kinetic data show that B[a]P and its metabolites are captured for a
prolonged time in the blood (Figure 7A). This lowers intracellular
peak concentrations preventing enzyme induction of Cyp1a1 and
1b1 responsible for the formation of 7,8,-diol-9,10-epoxide-B[a]P
[26].
In conclusion, we demonstrated that a vaccination against
B[a]P using promiscuous T-helper cell epitopes as carriers is
feasible. Some peptide conjugates were more immunogenic and
induced more and better antibodies against the hapten. We further
showed that appropriate small peptide carriers can redirect the
antibody response against the hapten at the detriment of the B cell
response to the carrier. This effect may partially explain the
improved response to these peptide conjugates. Pre-exposure to
TT did not negatively affect the immune response against B[a]P-
peptide or B[a]P-TT conjugates. This lends further support to the
use of TT derived peptides or protein as carriers for an
immunoprophylactic conjugate vaccine against low molecular
weight carcinogens such as B[a]P. While we demonstrated
previously that our vaccination strategy is protective against short
term adverse effects of B[a]P, such as immunotoxicity [26] and
neurotoxicity (unpublished data), further studies to demonstrate a
long term protection against carcinogenesis are needed.
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